← Home
Mike and Aubrey dig through the sensational claims around GLP-1 drugs like Ozempic and Wegovy, examining the gap between clinical trial data and media hype. They trace how these drugs became framed as the end of the obesity epidemic despite limited long-term data and significant side effects.
This summary was generated from show notes and public descriptions, not from a full transcript review. Details may contain inaccuracies.
Canon
•
Hobbes traces the pattern: fen-phen (1990s), Meridia (2000s), Contrave (2010s), Ozempic (2020s) — each declared the 'end of obesity,' each producing modest results with significant side effects, each replaced by the next miracle.
•
Gordon traces how the Ozempic-as-miracle-cure narrative spread through media, celebrity endorsements, and social media long before long-term safety data existed. The exciting false story traveled faster than the nuanced true story.
•
Gordon applies Stoic reasoning: body weight is largely outside individual control (genetics, metabolism, environment), but health behaviors (movement, nutrition quality, stress management) are within control and produce health benefits independent of weight change.
Highlights
•
Medical interventions for weight loss are judged by a different standard than other drugs -- modest efficacy is celebrated as revolutionary
Hobbes highlights that Ozempic produces average weight loss of 15% of body weight, which is celebrated as miraculous for a weight loss drug but would be considered modest for most other medical interventions. The framing reveals a double standard in how we evaluate treatments for fat bodies.Was this useful?